PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec.…
- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain…
In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…